Belite Bio, Inc
tinlarebant
Stargardt disease type 1 (STGD1)
Resolved
25days ago
Catalyst readout · Jun 12, 2026
What's at stake
A key catalyst for tinlarebant (Stargardt disease type 1 (STGD1)) is expected Jun 12, 2026.
Primary source
· SEC 6-K
verified 13h ago
“On June 12, 2026, Belite Bio, Inc issued a press release entitled “Belite Bio Completes Rolling Submission of New Drug Application to U.S. Food and Drug Administration for Tinlarebant for the Treatment of Stargardt Disease Type 1.””